Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer

RK Ramanathan, DD von Hoff, Ferry Eskens, G Blumenschein, D Richards, I Genvresse, S Reschke, C Granvil, A Skubala, C Pena, K Mross

Research output: Contribution to journalArticleAcademic

33 Citations (Scopus)
Original languageEnglish
Pages (from-to)163-174
Number of pages12
JournalTargeted Oncology
Volume15
Issue number2
DOIs
Publication statusPublished - 2020

Research programs

  • EMC OR-01

Cite this